Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing
Reexamination Certificate
2004-09-16
2009-11-03
Jones, D L (Department: 1618)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
C424S001110, C424S001650, C424S001810, C534S014000
Reexamination Certificate
active
07611693
ABSTRACT:
Compositions for imaging pancreatic beta cells comprise chelator-antidiabetic agent conjugates and optionally chelated metals.
REFERENCES:
patent: 4379785 (1983-04-01), Weyer et al.
patent: 4816484 (1989-03-01), Toyoshima et al.
patent: 4915931 (1990-04-01), Yokoyama et al.
patent: 4994258 (1991-02-01), Burns et al.
patent: 5094837 (1992-03-01), Bis
patent: 5416105 (1995-05-01), Satoh et al.
patent: 5436169 (1995-07-01), Iovanna et al.
patent: 5463116 (1995-10-01), Sumikawa et al.
patent: 6312661 (2001-11-01), Reubi
patent: 6774109 (2004-08-01), Dunmore et al.
patent: 2002/0150896 (2002-10-01), Polonsky et al.
patent: 2002/0155064 (2002-10-01), Reubi
patent: 2002/0173636 (2002-11-01), Chen
patent: 2003/0032021 (2003-02-01), Curtis
patent: 57-102820 (1982-06-01), None
patent: 59-044329 (1984-03-01), None
patent: 59-193833 (1984-11-01), None
patent: 01-294700 (1989-11-01), None
patent: 05-186372 (1993-07-01), None
patent: WO 95/11006 (1995-04-01), None
patent: WO 01/44177 (2001-06-01), None
Moore et al, Diabetes, Oct. 2001, vol. 50, pp. 2231-2236.
Chachin, M., et al., “Nateglinide, A D-Phenylalanine Derivative Lacking Either a Sulfonylurea or Benzamido Moiety, Specifically Inhibits Pancreatic Beta-Cell-Type K(ATP) Channels,” J. Pharmacol. Exp. Ther. 304(3):1025-32 (2003).
Chatziioannou, A., et al., “Imaging and Localization of Pancreatic Insulinomas,” Journal of Clinical Imaging 25:275-283 (2001).
Chen, An-Shu, et al., “Antioxidant Activity of a Schiff Base of Pyridoxal and Aminoguanidine,” Free Radical Biology & Medicine, 35(11):1392-1403 (2003).
Del Frate, C., et al., “Advances in Imaging for Pancreatic Disease,” Curr Gastroenterol Rep. 4(2):140-8 (2002).
Hansen, A. M., et al., “Differential Interactions of Nateglinide and Repaglinide on the Human Beta-Cell Sulphonylurea Receptor 1,” Diabetes 51(9):2789-95 (2002).
Hu, S. and Wang, S., “Effect of Insulinotropic Agent Nateglinide on Kv and Ca(2+) Channels in Pancreatic Beta-Cell,” Eur. J. Pharmacol. 427(2):97-104 (2001).
Hu, S., et al., “Pancreatic Beta-Cell K(ATP) Channel Activity and Membrane-Binding Studies with Nateglinide: A Comparison with Sulfonylureas and Repaglinide,” J. Pharmacol. Exp. Ther. 293(2):444-52 (2000).
Kalra, Mannudeep K., et al., “Current Status of Imaging in Pancreatic Diseases,” Journal of Computer Assisted Tomography 26(5):661-675 (2002).
Malaisse, W. J., “On the Track to the Beta-Cell,” Diabetologia 44(4):393-406 (2001).
Meyer, M., “Structural Requirements of Sulphonylureas and Analogues for Interaction with Sulphonylurea Receptor Subtypes,” Br. J. Pharmacol. 128(1):27-34 (1999).
Moore, A., Bonner-Weir, S., and Weissleder, R., “Noninvasive In Vivo Measurement of Beta-Cell Mass in Mouse Model of Diabetes,” Diabetes 50(10):2231-6 (2001).
Muller, G., “The Molecular Mechanism of the Insulin-Mimetic/Sensitizing Activity of the Antidiabetic Sulfonylurea Drug Amaryl,” Mol. Med. 6(11):907-33 (2000).
Ohnota, H., “Novel Rapid- and Short-Acting Hypoglycemic Agent, A Calcium(2s)-2-Benzyl-3-(CisHexahydro-2-lsoindolinylcarbonyl) Propionate (KAD-1229) That Acts on the Sulfonylurea Receptor: Comparison of Effects Between KAD-1229 and Gliclazide,” J. Pharmacol. Exp. Ther. 269(2):489-95 (1994).
Panten, U., Schwanstecher, M., and Schwanstecher, C., “Sulfonylurea Receptors and Mechanism of Sulfonylurea Action,” Exp. Clin. Endocrinol Diabetes 104(1):1-9 (1996).
International Search Report dated Jan. 13, 2005.
Harris, et al., “Design, Synthesis, and Evaluation of Radiolabeled Integrin αvβ3Receptor Antagonists for Tumor Imaging and Radiotherapy,” Cancer Biotherapy & Radiopharmaceuticals, vol. 18:4, pp. 627-641 (2003).
Wild, et al., “DOTA-NOC, A High-Affinity Ligand of Somatostatin Receptor Subtypes 2, 3 and 5 for Labelling with Various Radiometals,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 30:10, pp. 1338-1347 (2003).
Heindel, et al, “Syntheses and Tissue Distribution of99MTc-Sulfonylureas,” Journal of Pharmaceutical Sciences, vol. 64, No. 4, pp. 687-689 (1975).
Rosiere, et al, “Intraoperative gamma probe detection of insulinoma in an elderly patient with pancreatic cystic lesions,” Clinical Endocrinology GV, vol. 57, No. 4, pp. 547-549 (2002).
Supplemental European Search Report dated Jun. 4, 2009.
Azhdarinia Ali
Bryant Jerry
Kohanim Saady
Oh Chang-Sok
Yang David J.
Board of Regents, The Univerisity of Texas System
Jones D L
Vinson & Elkins LLP
LandOfFree
Mechanism-based targeted pancreatic beta cell imaging and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mechanism-based targeted pancreatic beta cell imaging and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mechanism-based targeted pancreatic beta cell imaging and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4111926